NeuroMetrix, Inc. (NURO) Insider Thomas T. Higgins Purchases 3,500 Shares of Stock

NeuroMetrix, Inc. (NASDAQ:NURO) insider Thomas T. Higgins acquired 3,500 shares of the firm’s stock in a transaction on Thursday, June 15th. The stock was bought at an average price of $2.98 per share, with a total value of $10,430.00. Following the purchase, the insider now directly owns 14,963 shares of the company’s stock, valued at $44,589.74. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

NeuroMetrix, Inc. (NASDAQ:NURO) traded down 4.33% on Friday, reaching $2.87. 77,713 shares of the company traded hands. The company has a 50-day moving average price of $2.69 and a 200-day moving average price of $1.21. The company’s market capitalization is $3.64 million. NeuroMetrix, Inc. has a 12 month low of $2.76 and a 12 month high of $16.00.

NeuroMetrix (NASDAQ:NURO) last issued its quarterly earnings data on Thursday, April 20th. The medical device company reported ($7.28) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.92) by $3.36. The firm had revenue of $4.31 million during the quarter, compared to the consensus estimate of $4.17 million. NeuroMetrix had a negative net margin of 99.95% and a negative return on equity of 175.24%. Equities research analysts expect that NeuroMetrix, Inc. will post ($10.50) EPS for the current year.

Insider Buying and Selling by Quarter for NeuroMetrix (NASDAQ:NURO)

WARNING: This report was first posted by sleekmoney and is the property of of sleekmoney. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at

Several equities analysts have issued reports on NURO shares. HC Wainwright set a $16.00 price objective on shares of NeuroMetrix and gave the company a “buy” rating in a research note on Thursday. Zacks Investment Research raised shares of NeuroMetrix from a “sell” rating to a “buy” rating and set a $6.00 target price for the company in a report on Wednesday, March 8th. Finally, ValuEngine cut shares of NeuroMetrix from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.

An institutional investor recently raised its position in NeuroMetrix stock. Sabby Management LLC boosted its stake in shares of NeuroMetrix, Inc. (NASDAQ:NURO) by 81.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 302,104 shares of the medical device company’s stock after buying an additional 135,836 shares during the period. Sabby Management LLC owned 2.98% of NeuroMetrix worth $187,000 at the end of the most recent quarter. 64.07% of the stock is currently owned by institutional investors and hedge funds.

NeuroMetrix Company Profile

NeuroMetrix, Inc is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests.

This story was originally published by sleekmoney ( and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for NeuroMetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix Inc. and related companies with's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *